ICAN, International Cancer Advocacy Network

ICAN's mission is life extension and quality of life for Stage IV cancer patients. ICAN, International Cancer Advocacy Network, is one of the country's foremost cancer patient advocacy organizations and Platinum-rated charitable organizations (EIN 86-0818253), providing late-stage cancer patients with the best information resources to be found anywhere in addition to new strategic options and clinical trials enrollment possibilities. Please check out our website, https://askican.org for a comprehensive listing of all of our patient services areas. We are daily dealing with a wide cross section of stakeholders in the global cancer community. ICAN oversees the following biomarker-specific organizations: Biomarker Collaborative; the Exon 20 Group (EGFR Exon 20 Warriors and HER2 Warriors); the MET Crusaders; the NRG1 Energizers; and the PD-L1 Amplifieds. All of our efforts are U.S.-based (coast to coast); global (all continents); pan-tumor; and multi-stakeholder. In addition to our Biomarkers Council, we have an International Research Consortium devoted to the cure of rare cancers.

Please follow Marcia Horn, our CEO, on linkedin. Please follow Marcia on X at @exon20group or @metcrusaders or @biomarkersrule, or @WarOnCancer

ICAN operates with the highest standards of board governance. We are grateful to our scientists, clinicians, drug discoverers, and drug developers who have made our professional councils indispensable.